65,437 trials
Cytomegalovirus Infections
Primary: Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation — 11; 20 participants — p=0.789
Osteoarthritis, Knee
Primary: Measure: Pain On Movement (POM) — 42.9; 42.1 units on a scale
Diabetes During Pregnancy · Gestational Diabetes
Primary: Compliance With Home Blood Glucose Reporting — 89.3; 87.6 percentage of expected glucose tests
Trauma
Primary: 24-hour Mortality — 43; 58 participants — p=0.12
Pain, Postoperative
Primary: Postoperative Opioid Use During the Postanesthesia Care Unit (PACU) Stay, and the First 24 Hours Postoperatively — 5.3; 5.2; 39.6; 32.7 mg — p=0.828
Transfusional Iron Overload · Beta-thalassemia
Primary: Change From Baseline in Liver Iron Concentration (LIC) at 96 Weeks — -1.75 mg/g — p=0.0765
Iron, Abnormal Blood Level · Other Abnormal Blood Chemistry
Primary: Measure of Non-transferrin-bound Iron — 0.16; 3.17 μM
Adult Glioblastoma · Adult Gliosarcoma · Recurrent Adult Brain Neoplasm
Primary: Progression-free Survival — 17.1; 9.7 Proportion of Successes
Neuromuscular Blockade · ECT
Primary: Optimal Dose of Neuromuscular Blocking Agent During ECT — 0.85; 0.41 mg.kg-1
Familial Hypercholesterolemia
Primary: Low Density Lipoprotein Cholesterol (LDL-C; Millimoles Per Liter [mMol/L]) During the Study — 6.304; 5.921; 4.087; 3.675 mMol/L
Schizophrenia · Mental Disorder · Nervous System Diseases
Primary: Number of Participants With Adverse Events (AEs). — 112; 4; 112; 2 participants
Alcoholism
Primary: Rate of Heavy Drinking Days Per Week. — .89; 1.21 rate of heavy drinking days per week — p=0.10
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Among Erlotinib-Treated Participants With the EGFR Mutation — 13.7 months
Postoperative Pain
Primary: Type of Chronic Pain After Hysterectomy — 5; 4; 6; 1 participants
Drug Interactions
Primary: AUC of Bosentan — 9540; 5710; 5020 h*ng/ml